This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Echo Therapeutics, Inc. (Nasdaq: ECTE) Provides An Update To Shareholders

Upcoming Catalysts

Building on the strong foundation with which we finished 2012, Echo is focused on completing several key milestones during 2013 that will enable us to begin generating revenue.

  • Echo expects to achieve International Standards Organization (IS0) 13485 certification in the first quarter of 2013.  ISO 13485 is the globally recognized Quality System standard that prescribes consistent processes for the development, design and manufacturing of medical devices, and is considered a step towards securing product commercialization approval by European and other international regulatory agencies.
  • Echo is preparing for a multi-center European regulatory trial of the Symphony tCGM System in critically ill patients and a subsequent Conformite Europeenne (CE) Technical File submission in the first half of 2013.  CE Marking would enable the commercial sale of Symphony in the EU and other countries that recognize the CE Mark.
  • In anticipation of a review of and determination regarding its CE Mark application in the second half of 2013, Echo has begun significant commercial planning activities.  Echo is preparing for European launch in target markets by the end of the year.
  • Echo is intensifying partnership discussions as Symphony nears commercialization.  The company is exploring a variety of partnership opportunities that exist in both the critical care and outpatient settings, and across numerous geographical areas.
  • Echo expects to meet with the Food & Drug Administration (FDA) in early 2013 to discuss the proposed pivotal clinical study during a Pre-PMA Submission meeting.   We plan to commence the pivotal clinical trial in the second half of 2013.  The safety and efficacy data obtained from the pivotal trial are expected to support a Premarket Approval application.
  • Echo plans to increase its scientific communication via oral presentations, poster sessions, and exhibitions at major medical meetings in Europe and the U.S., to strengthen awareness in the key opinion leader community.
  • Echo will provide continued communication with the investment community through upcoming investor conferences and regular updates on the company's progress.

Thank you for your investment in the continued success of our company.  We look forward to keeping you informed of our progress throughout the year.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,123.59 -49.09 -0.29%
S&P 500 1,991.32 -2.97 -0.15%
NASDAQ 4,529.3790 +1.69 0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs